Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director · CEO and President | September 08, 2026 | September 08, 2026 |
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date September 08, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 17,217 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 2,500 · Balance 19,717 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Row 2 · 2026-09-08 · Sale · Disposed 2,500 · Balance 17,217 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-02-24 | Direct | 274,430 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 2,500 · Balance 274,430 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.
KIORA PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2036-06-10 | Direct | 25,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 25,000 · Balance 25,000 F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 8, 2026 22:08 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-060962 · wk-form4_1788905328.xml · derivative · entry 3 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,430 Underlying: Class A Common Stock · 2,500 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 22:08 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 2,500 | $16.46 | $41,141.50 |
DisclosureSEC source: 0001628280-26-060962 · wk-form4_1788905328.xml · nonDerivative · entry 2 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,217 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 22:08 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 2,500 | $1.01 | $2,525.00 |
DisclosureSEC source: 0001628280-26-060962 · wk-form4_1788905328.xml · nonDerivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 22:14 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-052031 · wk-form4_1785795270.xml · derivative · entry 3 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,930 Underlying: Class A Common Stock · 2,500 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 22:14 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 2,500 | $16.01 | $40,029.00 |
DisclosureSEC source: 0001628280-26-052031 · wk-form4_1785795270.xml · nonDerivative · entry 2 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,217 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.06, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 22:14 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 2,500 | $1.01 | $2,525.00 |
DisclosureSEC source: 0001628280-26-052031 · wk-form4_1785795270.xml · nonDerivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| July 08, 2026 Filed Jul 8, 2026 22:49 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-047710 · wk-form4_1783550956.xml · derivative · entry 3 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 279,430 Underlying: Class A Common Stock · 2,500 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. Read SEC document |
| July 08, 2026 Filed Jul 8, 2026 22:49 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001628280-26-047710 · wk-form4_1783550956.xml · nonDerivative · entry 2 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,217 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| July 08, 2026 Filed Jul 8, 2026 22:49 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 2,500 | $1.01 | $2,525.00 |
DisclosureSEC source: 0001628280-26-047710 · wk-form4_1783550956.xml · nonDerivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · derivative · entry 5 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,417 Underlying: Class A Common Stock · 2,500 shares Expires 2028-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · derivative · entry 4 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,930 Underlying: Class A Common Stock · 7,500 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 10,000 | $16.01 | $160,080.00 |
DisclosureSEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · nonDerivative · entry 3 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,217 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 5,605 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 2,500 | $1.26 | $3,150.00 |
DisclosureSEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · nonDerivative · entry 2 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 7,500 | $1.01 | $7,575.00 |
DisclosureSEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · nonDerivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001861519-26-000002 · wk-form4_1781295377.xml · derivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:40 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 2,700 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-26-005892 · rdgdoc.xml · derivative · entry 6 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,917 Underlying: Class A Common Stock · 2,700 shares Expires 2028-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:40 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 2,700 | $16.02 | $43,241.85 |
DisclosureSEC source: 0001437749-26-005892 · rdgdoc.xml · nonDerivative · entry 4 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,954 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:40 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 2,700 | $1.26 | $3,402.00 |
DisclosureSEC source: 0001437749-26-005892 · rdgdoc.xml · nonDerivative · entry 3 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:40 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 4,400 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-26-005892 · rdgdoc.xml · derivative · entry 5 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,617 Underlying: Class A Common Stock · 4,400 shares Expires 2028-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:40 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 4,400 | $16.02 | $70,485.80 |
DisclosureSEC source: 0001437749-26-005892 · rdgdoc.xml · nonDerivative · entry 2 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,954 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:40 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 4,400 | $1.26 | $5,544.00 |
DisclosureSEC source: 0001437749-26-005892 · rdgdoc.xml · nonDerivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:27 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-26-004126 · rdgdoc.xml · derivative · entry 3 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,017 Underlying: Class A Common Stock · 400 shares Expires 2028-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · derivative.exercise_date: The stock options are fully vested and exercisable. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:27 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 400 | $16.00 | $6,400.00 |
DisclosureSEC source: 0001437749-26-004126 · rdgdoc.xml · nonDerivative · entry 2 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,954 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:27 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 400 | $1.26 | $504.00 |
DisclosureSEC source: 0001437749-26-004126 · rdgdoc.xml · nonDerivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · balance_after: Includes 1,246 shares purchased through Issuer's Employee Stock Purchase Plan on November 15, 2024 and 2,096 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2025. Read SEC document |
| January 30, 2026 Filed Jan 30, 2026 21:56 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 445,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001437749-26-002577 · rdgdoc.xml · derivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,000 Underlying: Class A Common Stock · 445,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:11 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001372514-25-000026 · wk-form4_1743639103.xml · derivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026. Read SEC document |
| January 31, 2025 Filed Jan 31, 2025 21:35 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001437749-25-002424 · rdgdoc.xml · derivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Common Stock · 300,000 shares Expires 2035-01-30 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 10:32 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | PurchaseCommon Stock | 1,250 | $3.68 | $4,600.00 |
DisclosureSEC source: 0001372514-24-000115 · wk-form4_1726137169.xml · nonDerivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.65 to $3.73. The reported price of $3.68 represents the volume weighted average price for the reported transaction. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 1,778 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001372514-24-000093 · wk-form4_1720034163.xml · derivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,778 Underlying: Common Stock · 1,778 shares Expires 2034-07-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:59 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 285,000 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018626 · rdgdoc.xml · derivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Class A Common Stock · 285,000 shares Expires 2034-05-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:45 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001372514-23-000145 · wk-form4_1696365916.xml · derivative · entry 1 Stengone Carmine N. · CIK 0001861519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.